New York, New York--(Newsfile Corp. - March 25, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

NKTR Shareholder Alert: May 5, 2026 Lead Plaintiff Deadline in Nektar Therapeutics Securities Class Action Lawsuit -- The Gross Law Firm Accessibility StatementSkip NavigationNEW YORK, March 24, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Nektar Therapeutics (NASDAQ: NKTR).Shareholders who purchased shares of NKTR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not req ...

New York, New York--(Newsfile Corp. - March 24, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Nektar Therapeutics (NASDAQ: NKTR) between February 26, 2025 and December 15, 2025, both dates inclusive (the "Class Period"), of the important May 5, 2026 lead plaintiff deadline.SO WHAT: If you purchased Nektar securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee ar ...

Robbins LLP Urges NKTR Stockholders Who Lost Money Investing in Nektar Therapeutics to Contact the Firm for Information About Leading the Class Action Accessibility StatementSkip Navigation SAN DIEGO, March 23, 2026 /PRNewswire/ -- Robbins LLPreminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Nektar Therapeutics (NASDAQ: NKTR) securities between February 26, 2025 and December 15, 2025. Nektar is a biopharmaceutical company focused on discovering ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, of the May 5, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Nektar securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The lawsuit alleges that defendants made false or misleading statements regarding the REZOLVE-AA trial, which could have negatively impacted its results and misled investors [4]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [3].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nektar Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and trial results [2][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Nektar to contact them for discussing legal options [1]. - The firm has set a deadline of May 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Nektar [2]. - The complaint alleges that Nektar and its executives made false statements regarding the REZOLVE-AA trial, which could significantly impact the trial's results and integrity [5]. Group 2: Trial Results and Stock Impact - On December 16, 2025, Nektar announced that the Phase 2b REZOLVE-AA trial failed to reach statistical significance, attributing this to the inclusion of ineligible patients [6]. - Following the announcement, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, of the May 5, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who bought Nektar securities during the specified period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6] - The deadline to move the Court to serve as lead plaintiff is May 5, 2026, with the lead plaintiff representing other class members in the litigation [3] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements, including the largest securities class action settlement against a Chinese company [4] - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4] - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4] Group 3: Case Specifics - The lawsuit alleges that defendants made false or misleading statements regarding the REZOLVE-AA trial, including improper enrollment and overstated trial integrity, which negatively impacted investors when the truth emerged [5]

Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit Deadline Alert: Nektar Therapeutics (NKTR) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit Share LOS ANGELES--(BUSINESS WIRE)-- Glancy Prongay Wolke & Rotter LLPreminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors ...

Data from Phase 2b Studies for Rezpegaldesleukin Accepted for Two Oral Presentations at the 2026 American Academy of Dermatology Annual Meeting Accessibility StatementSkip Navigation SAN FRANCISCO, March 20, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that data from the ongoing Phase 2b studies of rezpegaldesleukin in atopic dermatitis and alopecia areata have been accepted for two oral presentations at the 2026 American Academy of Dermatology (AAD) Annual Meeting taking place Ma ...

Abivax - Abivax is developing obefazimod, a potential blockbuster therapy for chronic inflammatory diseases, currently in phase 3 trials for ulcerative colitis and phase 2b trials for Crohn's disease [2][3] - The ulcerative colitis market is projected to grow from $8.7 billion in 2026 to $14.3 billion by 2035, indicating significant market potential for obefazimod [4] - Abivax has seen a share price increase of over 1,900% in the past year, driven by positive clinical trial results and rumors of potential buyout interest from companies like Eli Lilly and AstraZeneca [6] - The company reported €589.7 million (approximately $697 million) in cash and equivalents, sufficient to fund operations into Q4 2027 [8] Nektar Therapeutics - Nektar's lead candidate, rezpegaldesleukin, has shown promising results in phase 2b trials for moderate-to-severe atopic dermatitis, with over 80% of patients achieving significant skin improvement [10] - The drug is also being tested for multiple indications, including alopecia areata, type 1 diabetes, and multiple sclerosis, enhancing its potential as a "pipeline-in-a-drug" [11] - Following a $460 million capital raise, Nektar has over $700 million in liquidity, allowing it to fund operations into 2027, with analysts projecting significant upside in stock price [12] - Nektar is considered a potential acquisition target for larger pharmaceutical companies, including Sanofi and AbbVie, which could see strategic value in its pipeline [13]